1. Cancer Cell. 2015 Jul 13;28(1):29-41. doi: 10.1016/j.ccell.2015.06.005.

Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic 
Leukemia.

Wu SC(1), Li LS(2), Kopp N(1), Montero J(1), Chapuy B(1), Yoda A(1), Christie 
AL(1), Liu H(1), Christodoulou A(1), van Bodegom D(1), van der Zwet J(1), Layer 
JV(1), Tivey T(1), Lane AA(1), Ryan JA(1), Ng SY(1), DeAngelo DJ(1), Stone 
RM(1), Steensma D(1), Wadleigh M(1), Harris M(3), Mandon E(4), Ebel N(4), 
Andraos R(4), Romanet V(4), Dölemeyer A(4), Sterker D(4), Zender M(4), Rodig 
SJ(5), Murakami M(4), Hofmann F(4), Kuo F(5), Eck MJ(6), Silverman LB(3), Sallan 
SE(3), Letai A(1), Baffert F(4), Vangrevelinghe E(4), Radimerski T(4), Gaul 
C(7), Weinstock DM(8).

Author information:
(1)Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 
02215, USA.
(2)Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 
02215, USA; Department of Pediatric Oncology, Dana-Farber Cancer Institute, 
Boston, MA 02215, USA.
(3)Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 
02215, USA.
(4)Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland.
(5)Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, USA.
(6)Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, 
USA.
(7)Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland. 
Electronic address: christoph.gaul@novartis.com.
(8)Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 
02215, USA; Broad Institute, Cambridge, MA 02142, USA. Electronic address: 
dweinstock@partners.org.

Comment in
    Cancer Cell. 2015 Jul 13;28(1):1-2. doi: 10.1016/j.ccell.2015.06.010.

A variety of cancers depend on JAK2 signaling, including the high-risk subset of 
B cell acute lymphoblastic leukemias (B-ALLs) with CRLF2 rearrangements. Type I 
JAK2 inhibitors induce paradoxical JAK2 hyperphosphorylation in these leukemias 
and have limited activity. To improve the efficacy of JAK2 inhibition in B-ALL, 
we developed the type II inhibitor CHZ868, which stabilizes JAK2 in an inactive 
conformation. CHZ868 potently suppressed the growth of CRLF2-rearranged human 
B-ALL cells, abrogated JAK2 signaling, and improved survival in mice with human 
or murine B-ALL. CHZ868 and dexamethasone synergistically induced apoptosis in 
JAK2-dependent B-ALLs and further improved in vivo survival compared to CHZ868 
alone. These data support the testing of type II JAK2 inhibition in patients 
with JAK2-dependent leukemias and other disorders.

Copyright © 2015 Elsevier Inc. All rights reserved.

DOI: 10.1016/j.ccell.2015.06.005
PMCID: PMC4505625
PMID: 26175414 [Indexed for MEDLINE]

Conflict of interest statement: Declaration of Potential Conflicts of Interest 
E.M., N.E., R.A., V.R., A.D., D.S., M.Z., M.M., F.H., F.B., E.V., T.R. and C.G. 
are or have been employees of Novartis Pharma AG. M.J.E. and D.M.W. received 
research funding from Novartis.